ASCO publishes updated multiple myeloma Living Guidelines
The American Society of Clinical Oncology published updated Living Guidelines for treatment of multiple myeloma (MM) in the Journal of Clinical Oncology.
Ultra–low-dose radiation therapy may help relieve myeloma-related bone pain
According to findings from a prospective phase 2 trial, presented at the 2026 American Society of Radiation Oncology Annual Meeting, an ultra-low dose of radiation therapy — 4 Gy delivered over one or two treatments, directed at uncomplicated bone lesions
— improved pain in patients with MM; 81% of patients achieved pain control without additional radiation. Notably, there were no hematologic toxicities ≥grade 3.
Felzartamab triplet extends PFS in patients with RRMMF
Felzartamab, a novel anti-CD38 monoclonal antibody, when combined with lenalidomide and dexamethasone, improved progression-free survival (PFS), compared with lenalidomide-dexamethasone, in patients with relapsed/refractory MM
(RRMM). These findings, from an open-label randomized phase 3 trial conducted in China, were reported in The Lancet Haematology.
Novel bispecific forimtamig demonstrates efficacy in RRMM
A subcutaneous formulation of the novel GPRC5DxCD3 bispecific antibody forimtamig demonstrated an overall response rate (ORR) of 59.6% in a phase 1 trial that included 171 patients with RRMM, 60.2% of whom had triple drug class-refractory disease. The findings were reported in Blood Advances.
Iberdomide-daratumumab combination improves MRD-negative CR in RRMM
The phase 3 EXCALIBER-RRMM trial showed near doubling of minimal residual disease (MRD)-negative complete response (CR) rates, 41% vs 21%, among patients with RRMM who received iberdomide-daratumumab-
Serum MS-based MRD shows comparable prognostic performance with bone marrow MRD analyses
In a retrospective post-hoc analysis of the CASSIOPET companion study to the phase 3 CASSIOPEIA trial, prospectively collected paired serum and bone marrow samples were used to assess MRD via mass spectrometry (MS; in serum) or next-generation sequencing /next-generation flow (NGS/NGF; in bone marrow). Data published in Blood showed comparable landmark prognostic performance across different methods, with MRD-negativity correlating with longer PFS. The findings “support a complementary, phase-adapted role for serum MS alongside bone marrow MRD testing,” authors concluded.
Blood-based technologies for myeloma diagnosis and disease monitoring were discussed during a core session at the 23rd IMS Annual Meeting.
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
